Searchable abstracts of presentations at key conferences in endocrinology

ea0086p238 | Neuroendocrinology and Pituitary | SFEBES2022

Anticoagulation practice for venous thromboembolism prophylaxis in patients with Cushing’s Syndrome - a Society for Endocrinology survey of UK Centres

Isand Kristina , Plummer Zoe E , Volke Vallo , Newell-Price John , Wass John , Pal Aparna

Background: CushingÂ’s syndrome (CS) is estimated to have a 10-fold increased risk of venous thromboembolism (VTE) compared with the normal population with VTE accounting for 3.6-11% deaths in CS patients. There are no specific guidelines for VTE prophylaxis in CS other than that it should be considered given the increasingly recognised risk.Methods: Via the Society for Endocrinology, we surveyed current VTE anticoagulation practice across UK Endocri...

ea0070aep657 | Pituitary and Neuroendocrinology | ECE2020

The impact of variations in laboratory measurements of IGF-1 and random growth hormone on the classification of acromegaly disease activity status: Lessons from the UK Acromegaly Register Reference Laboratory

Bashir Bilal , Adam Safwaan , Monaghan Philip , Plummer Zoe , Archer Natasha , Ayuk John , Trainer Peter

Background: The UK Acromegaly Register contains data for 2700 patients. IGF-1 and random growth hormone (GH) measurements are used for disease monitoring. The registry reference laboratory (RRL) uses the Immunodiagnostic systems (IDS)-iSYS immunoassay platform for GH and IGF-1. The RRL uses age- and sex-specific reference ranges for IGF-1. We compared IGF-1 and GH results fromlocal laboratories to those of the RRL (pre-defined as the Gold standard) to determine the extent of d...

ea0077p81 | Neuroendocrinology and Pituitary | SFEBES2021

Is gigantism different from acromegaly in terms of causes of death, comorbidities and treatment? A preliminary retrospective study of 156 UK giants

Kaniuka-Jakubowska Sonia , Abeyaratne Dayakshi , Pal Aparna , Plummer Zoe , Archer Natasha , Ayuk John , Kaszubowski Mariusz , Wass John , Korbonits Marta

Introduction: Although acromegaly and pituitary gigantism have the same pathological cause, they have different disease characteristics.Aim: To study tumour size, treatment course and the most common comorbidities in a population with young-onset acromegaly.Materials and Methods: UK Acromegaly Register (UKAR, 22 centres, 1997-2017) retrospective analysis, enriched with patients from the FIPA-consortium. We defined gigantism as diag...

ea0077op3.1 | Reproductive and Neuroendocrinology | SFEBES2021

Discordant growth hormone and insulin like growth factor-1 values are associated with an increased mortality over concordant normal values in patients treated for acromegaly

Abeyaratne Dayakshi , Kaniuka-Jakubowska Sonia , Plummer Zoe , Archer Natasha , Lakmal Fonseka Chathuranga , Ayuk John , Peter James , McNally Richard , Michael Orme Stephen , Rees Aled , Pal Aparna , Wass John

Background: Growth hormone (GH) and Insulin like growth factor 1 (IGF-1) discordance in patients with acromegaly is a well-recognised phenomenon. It is unclear whether this is associated with increased mortality and morbidity compared to patients with concordant normal results.Methodology: A retrospective study was conducted on the United Kingdom Acromegaly Registry (UKAR). A comparison of mortality and morbidity was performed among four groups categoris...